Year-end Sale % OFF 
Abstract
Background and AimsThere is limited data on hepatitis C (HCV) treatment uptake among people who inject drugs including individuals receiving opioid substitution treatment (OST). We aimed to calculate cumulative HCV treatment uptake, estimate annual treatment rates, and identify factors associated with HCV treatment among individuals who have received OST in Norway.MethodsThis observational study was based on linked data from The Norwegian Prescription Database and The Norwegian Surveillance System for Communicable Diseases between 2004 and 2013. Both registries have national coverage. From a total of 9919 individuals who had been dispensed OST (methadone, buprenorphine or buprenorphine-naloxone), we included 3755 individuals who had been notified with HCV infection. In this population, dispensions of HCV treatment (pegylated interferon and ribavirin), benzodiazepines, selective serotonin reuptake inhibitors and antipsychotics were studied.ResultsAmong 3755 OST patients notified with HCV infection, 539 (14%) had received HCV treatment during the study period. Annual HCV treatment rates during OST ranged between 1.3% (95% confidence interval [CI] 0.7–2.2) in 2005 and 2.6% (95% CI 1.9–3.5) in 2008 with no significant changes over time. HCV treatment uptake was not associated with age or gender, but associated with duration of active OST (adjusted odds ratio [aOR] 1.11 per year; 95% CI 1.07–1.15), high (> 80%) OST continuity (aOR 1.62; 95% CI 1.17–2.25), and heavy benzodiazepine use (aOR 0.65; 95% CI 0.49–0.87).ConclusionsCumulative HCV treatment uptake among OST patients notified with HCV infection in Norway between 2004 and 2013 was 14%. Annual treatment rates during OST remained unchanged below 3% per year. High continuity of OST over time and absence of heavy benzodiazepine use predicted HCV treatment uptake. Increased awareness for HCV among OST patients is needed as tolerable and efficient directly acting antiviral treatment is being introduced.
Highlights
In high-income countries, transmission of hepatitis C virus (HCV) infection mainly occurs among people who inject drugs (PWID) [1]
Annual HCV treatment rates during opioid substitution treatment (OST) ranged between 1.3% (95% confidence interval [CI] 0.7–2.2) in 2005 and 2.6% in 2008 with no significant changes over time
HCV treatment uptake was not associated with age or gender, but associated with duration of active OST, high (> 80%) OST continuity, and heavy benzodiazepine use
Summary
In high-income countries, transmission of hepatitis C virus (HCV) infection mainly occurs among people who inject drugs (PWID) [1]. HCV treatment for PWID has shown good outcomes [6, 7] and is recommended by international guidelines [8,9,10,11], treatment uptake has remained low in community-based cohorts of PWID (< 2% per year) [12,13,14,15] as well as in the general population (< 5% per year in most countries) [16, 17] This can be attributed to a number of treatment barriers, most notably the lack of suitable models of care and concerns of potential psychiatric adverse effects of interferon (IFN)-based treatment [18,19,20]. We aimed to calculate cumulative HCV treatment uptake, estimate annual treatment rates, and identify factors associated with HCV treatment among individuals who have received OST in Norway
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
